-
Regeneron Is 'One Of The Stronger Growers In Biotech'
Wednesday, June 29, 2016 - 3:04pm | 416Read More...Bernstein has initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with an Outperform rating and $400 price target, citing a "good entry point for one of stronger growers in biotech." "Regeneron is a growth-phase biopharma with one large successful first product (Eylea) and two...
-
UPDATE: Barclays Initiates Coverage On Regeneron
Tuesday, January 6, 2015 - 12:28pm | 200Read More...Geoffrey Meacham of Barclays initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Tuesday with an Equal-Weight rating and $450 price target as approval and modest growth profile of key drugs are already expected by investors. Based on Meacham's survey of 50 U.S....
